Company Overview and News

 
Kotak Bank, Bajaj Finserv, ABB results

2018-07-18 thehindubusinessline
Thursday will see a host of most actively tracked companies declaring their results for the period ended June 2018. Among these are 21st Century, AB Money, ABB, Bajaj Finserv, Bajaj Finance, Bharat Immunologicals, DB Corp, GNA Axles, Hatsun Agro, Integra Engineering, Kotak Mahindra Bank, Omax Autos, RBL Bank, Shree Digvijay Cement, Sterlite Technologies, Sagar Cements, South India Paper, Suraj, VLS Finance, Valecha Engineering and Vikas EcoTech.
VALECHAENG SAGCEM OMAXAUTO KMBKY SHREDIGCEM 532978 502090 STRTECH 511333 530961 VIKASECO 532389 SRLRY BAJAJFINSV 502180 BAJFINANCE 532374 KOTAKBANK BJJQY 520021 500247 VLSFINANCE 500034

4
IndusInd Bank, RPower results on Thursday

2018-04-18 thehindubusinessline
Over half-a-dozen companies will declare their quarterly and full-year results for the period ended March 2018 on Thursday. These are Bharat Seats, Cyient, IndusInd Bank, Infomedia Press, Mahindra CIE Automotive, Reliance Power, RS Software (India) and Shree Digvijay Cement Company. Focus will be on IndusInd Bank, a bank that has shown consistent growth in net profit over the years. Eyes will be on the NPA figure that the bank will disclose.
523229 BHARATSE RPOWER 532939 INDUSINDBK DABUR SHREDIGCEM 532756 DBRQY 500096 502180 532187 INFOMEDIA MAHINDCIE 509069

Related Articles

ALIM: Alimera Sciences Analysis and Research Report

2018-10-01 - Asif

Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...

DMPI: DelMar Pharmaceuticals Analysis and Research Report

2018-09-25 - Asif

Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...